Results 231 to 240 of about 20,320 (295)

Clinical potential of the gut microbiome in oncology: a scoping review of treatment response, toxicity and biomarker development. [PDF]

Support Care Cancer
de Souza Menezes JD, da Silva MQ, Dos Santos ER, de Carvalho SRPVT, Faria MAG, de Cássia Helú Mendonça Ribeiro R, André JC.   +6 more
europepmc   +1 more source

Mutagen-induced somatic mutation rate in primary mammalian cells in relation to maximum life span. [PDF]

Geromedicine
Heid J, Sun S, Ablaeva J, Lee M, Zhang Z, Gorbunova V, Seluanov A, Maslov AY, Vijg J.   +8 more
europepmc   +1 more source

Neural and Behavioral Correlates of Evidence Accumulation in Human Click-Based Echolocation. [PDF]

eNeuro
García-Lázaro HG, Teng S.
europepmc   +1 more source

Peroxiredoxin 1 inhibits tumorigenesis by activating the NLR family pyrin domain containing 3/gasdermin D pathway: Advanced therapies targeting heterogeneous cell death mechanisms. [PDF]

World J Gastroenterol
Smirnova A, Eygel D, Kondrasheva I, Baranovskii DS, Klabukov ID.   +4 more
europepmc   +1 more source

First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial.

JAMA Oncol
Yang Y, Yen CJ, Pan J, Wang H, Qu S, Chen N, Chen X, Sun Y, He X, Hu C, Lin L, Wu Y, Yuan S, Chen C, Xu X, Ma X, Leaw S, Zhang L, Fang W.   +18 more
europepmc   +1 more source

Short blind signatures [PDF]

Journal of Computer Security, 2013
Blind signatures allow users to obtain signatures on messages hidden from the signer; moreover, the signer cannot link the resulting message/signature pair to the signing session. This paper presents blind signature schemes, in which the number of interactions between the user and the signer is minimal and whose blind signatures are short.
Blazy, Olivier, Fuchsbauer, Georg, Pointcheval, David, Vergnaud, Damien   +3 more
openaire   +2 more sources